|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||10.36 - 10.57|
|52-week range||10.36 - 10.57|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).
BARCELONA, Spain, September 15, 2023--Almirall S.A. (BME: ALM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.
BARCELONA, Spain, July 24, 2023--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.